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Abstract
Uterine fibroid is the most encountered benign tumour in women of 
reproductive age. It causes spontaneous abortions, missed abortions, painful red 
degeneration or infarction of the fibroids, abnormal foetal presentation, obstructed 
labour, and an increased likelihood of premature deliveries, caesarean deliveries, 
postpartum haemorrhage in pregnancy, whereas, in the non-pregnant women 
it is associated an irregular menstrual cycle sometimes associated with heavy 
menstrual bleeding, infertility, constipation, urinary incontinence, and leiosarcoma 
transformation. Till date is pathophysiology and management both in the non-
pregnant and pregnant woman have not been well described. In this chapter, we 
present contemporary evidence to help elucidate this enigma.
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1. Introduction
Leiomyomas also called uterine myomas, uterine fibroids, or fibromyomas are 
discrete, rounded, firm, white to pale pink, benign myometrial tumours composed 
mostly of smooth muscle with varying amounts of fibrous connective tissues [1]. 
Uterine fibroids or leiomyomas are benign tumours of the uterine smooth muscles. 
They are benign clonal neoplasms that contain an increased amount of extracellular 
collagen, elastin and are surrounded by a thin pseudo-capsule. They may enlarge to 
cause significant distortion of the uterine surface or cavity. Their size will then be 
described in menstrual weeks, as in a pregnant uterus [2].
Most fibroids are asymptomatic; usually asymptomatic in pregnancy but may 
interfere with conception and may cause spontaneous abortion, missed abortions, 
painful red degeneration or infarction of the fibroids, abnormal foetal presenta-
tion, obstructed labour, and an increased likelihood of premature deliveries, 
caesarean deliveries, postpartum haemorrhage and, whereas, in the non-pregnant 
state its signs and symptoms are menorrhagia, metorrhagia, menometorrhagia, 
infertility, constipation, urinary incontinence, and leiosarcoma transformation 
[3]. Uterine fibroids can occur in the non-pregnant woman and then continue 
into pregnancy/may develop de novo in pregnancy. In both circumstances, the 





Evidence from the contemporary literature reports that the prevalence rate of 
uterine fibroid varies between 16.7% - 30% of reproductive-age women and there 
is a two-fold increase in the prevalence in Afro American women [4, 5]. Also, their 
incidence tends to peak at the age of 35 years and almost 50% of African women 
will have uterine fibroid by their 5th decade of life [1]. Leiomyomas are the most 
frequent pelvic tumours and occur in about 20 to 25% of reproductive-age women. 
Uterine fibroids and the severity of their symptoms have a predilection for the black 
ethnicity. Huyck KL et al. in 2008 demonstrated that the odds of having severe 
symptoms from uterine fibroids are more than five times greater in black African 
women than in Caucasians [6]. Furthermore, black women develop the disease five 
to six years earlier and their peak age at diagnosis is 40–44 years [7] as opposed to a 
to peak age of incidence of 35 years observed in Caucasians [1]. Also, almost 50% of 
African women will have uterine fibroid by their 5th decade of life [1].
Risks factors of uterine fibroids include African-American ethnicity, early 
menarche (less than 11 years) and high body mass index [8, 9]. Moreover, the length 
of the menstrual cycle has an inversely proportional relationship with fibroids: a 
shorter cycle is positively correlated with an increased likelihood to develop fibroids 
[10, 11]. A similar inverse association is observed with use of oral contraceptives, 
the duration of tobacco smoking and the development of fibroids [12]. On the other 
hand, multiparity and the late ages of last pregnancy are other protective factors for 
uterine fibroids [11].
3. Anatomical Classification of Uterine Fibroids
According to their anatomic locations, there are three different types of 
leiomyomas:
• Subserosal or subperitoneal leiomyomata are the most common and are 
usually asymptomatic unless very large. They originate in the myometrium 
and grow out toward the serosal surface of the uterus, lying beneath the 
peritoneum [1]. They may lie just at the serosal surface of the uterus or may 
become pedunculated. They become parasitic when they derive their entire 
blood supply outside of the uterus, from omental vessels. Sometimes, their 
pedicles may atrophy and resorb. When they arise laterally, subserous tumours 
may extend between the two peritoneal layers of the broad ligament to become 
intraligamentary leiomyomas.
• Intramural or interstitial myomas are located within the uterine wall of the 
myometrium and may distort the shape of the uterine cavity and surface. They 
may manifest with swelling of the abdomen, menorrhagia and infertility.
• Submucosal fibroids are the most symptomatic. They originate in the 
 myometrium and grow toward the endometrial cavity, protruding into the 
uterine cavity that they tend to compress. Their impact on the endometrium 
and its blood supply most often lead to irregular uterine bleeding. Other 
symptoms commonly associated are dysmenorrhea, infertility and recurrent 
abortions [13]. This type of fibroids may also develop pedicles and protrude 
fully into the uterine cavity. Occasionally they pass through the cervical canal 
while still attached within the corpus by a long stalk. There, they are subject to 
torsion or infection.
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• Cervical leiomyomas are a rare type. They are sometimes mistaken to vaginal 
leiomyomas, which may present with the same clinical features [14]. They 
cause early pressure effects in regions of bladder neck, infection, dyspareunia 
and infertility.
• With respect to the location of the fibroids, 89.4% submucous, 10.6% subse-
rous and 74.5% were intramural according to a study done in Cameroon [15].
FIGO classification of uterine fibroids (PALM-COEIN)
Stage 0: a sub-mucosal pedunculated intra-uterine cavity fibroid
Stage 1: a sub-mucosal located less than 50% intra-murally
Stage 2: a sub-mucosal located greater than 50% intra-murally
Stage 3: a fibroid which is 100% interstitially or intra-murally located in contact 
with the endometrium
Stage 4: a fibroid which is completely interstitially or intra-murally located
Stage 5: a sub-serosal fibroid which is greater than or equall to 50% intra-
murally located
Stage 6: a sub-serosal fibroid which is less than 50% intra-murally located
Stage 7: a sub-serosal pedunculated fibroid
Stage 8: others, parasite (round cervical ligament, large ligament).
4. Physiopathology of Uterine Fibroids
The cause of uterine leiomyomata is idiopathic till date. However, several 
hypotheses have been postulated, namely:
i. Glucose-6-phosphate dehydrogenase studies suggest that each individual 
leiomyoma is unicellular in origin that is monoclonal [2]. Hence, this implies 
a genetic probability for the growth of uterine.
ii. In increment in the exposure of circulating oestrogens is another hypothesis 
for the growth of uterine fibroids. Effectively, leiomyomas contain oestrogen 
receptors in higher concentrations than the surrounding myometrium. But at 
lower concentrations than the endometrium, this oestrogen may contribute to 
tumour enlargement by increasing the production of extracellular matrix. On 
the other hand, progesterone increases the mitotic activity of myomas in young 
women. It may allow for tumour enlargement by down-regulating apoptosis in 
the fibroids [16]. They usually decrease in size after menopause and whenever 
myomas grow after menopause, malignancy must be seriously considered [17].
Malignant transformation of leiomyomas is very rare, seen in 0.04% women 
having uterine fibroids. In a review of 13,000 leiomyomas, 38 cases (0.29%) dem-
onstrated malignant manifestations. A second study reported that malignant change 
developed in less than 0.13% of uterine leiomyomas [17]. The diagnosis of leiomyosar-
comas is based on the counts of 10 or more mitotic figures per 10 HPFs. Atypical leio-
myoma is differentiated from leiomyosarcoma by a lack of necrotizing tumour cells 
and a mitotic count less than 7 per 10 HPFs. Nuclear atypia makes the difference with 
mitotically active leiomyoma [18]. Secondary changes may occur when the fibroids 
tend to outgrow their blood supply. These degenerations include necrotic, haemor-
rhagic (red degeneration) or septic for the acute ones. Chronic degeneration may be 





Most at times, leiomyomas are asymptomatic. Symptoms are found only in about 
35–50% of the patients. They vary according to the type, location, size, number and 
vascular supply of the fibroids. These include:




Bleeding from the uterus is the most common symptom. It may either be  during 
the menstrual periods when the patient will have heavy and prolonged menses 
called menometorrhagia [16] or it may manifest as light spotting before and after 
the menses. The incidence of abnormal uterine bleeding was 47.7% in a study done 
by Okogbo et al. in 2011 in Nigeria [19]. This abnormal bleeding is due to the devel-
opment or dilatation of endometrial venules which increase the flow during cyclical 
sloughing or to the increase in size of the uterine cavity by the fibromyomas [17].
Pain may either be due to red degeneration, infarction or torsion of a uterine 
fibroid, or mat stem from attempts to expel a pedunculated submucousal fibroid 
[1]. A sensation of pelvic heaviness or fullness or a feeling of a mass in the pelvis is 
particularly characteristic of large tumours. These may press on nerves within the 
bony pelvis, creating pain that radiates to the back or lower extremities.
Pressure effects may either be anteriorly on the bladder, causing mainly fre-
quent micturation, and urinary incontinence. Laterally, myomas may compress the 
ureters, leading to hydroureters. When the base of the bladder is involved, urinary 
retention may occur. Posteriorly, fibroids may increase the rectal pressure or cause 
constipation or tenesmus. It should be noted that these pressure symptoms are quite 
unusual and are difficult to directly relate to fibroids.
The relationship between fibroids and infertility is not clear. Fibroids may have 
a detrimental effect on fertility in up to 10% of the cases [20]. Infertility may result 
because of impaired implantation, tubal function or sperm transport.
5.2 Diagnostic tests
The diagnosis of uterine fibroids is made from the signs and symptoms, pelvic 
examination, laboratory investigations and imaging.
Most leiomyomas are discovered by routine pelvic examination, when a firm 
mass of an irregular shape is felt in the uterus. To confirm the diagnosis different 
types of imaging techniques are used:
• A Pelvic ultrasound scan is the test of first choice. Here, three-dimensional 
scan is preferred to a two-dimensional scan due its higher resolution which 
helps to rule out a pregnancy, other pelvic masses, a congenital uterine 
 malformation [21].
• A magnetic resonance imaging is the gold standard test which is highly 
accurate in depicting the size, number and location of myomas to choose the 
therapeutical modality.
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• Saline sonohysterography can identify and characterise the location of 
submucosal myomas missed on classical abdominal or transvaginal ultrasound.
• Plain X-Rays of the lower abdomen and pelvis usually identify only calcified 
fibroids and sometimes large fibroids may be seen as soft tissue or calcified 
masses displacing bowel gas [22].
• Hysterosalpingography may be useful in the infertile patient. It evaluates the 
contour of the uterine cavity and the patency of fallopian tubes but does not 
evaluate the exact location of fibroids.
• CT scan is not the investigation of choice, fibroids may be detected inciden-
tally while investigating for another condition.
Laboratory investigations may reveal anaemia as a consequence of the 
 menometrorrhagia of fibroids and depletion of iron stores or leucocytosis and 
raised C-reactive proteins in case of acute degeneration or infection.
Differential diagnoses of leiomyomas include pregnancy, adenomyosis, 
 leiomyosarcoma, or solid ovarian neoplasms. Other conditions to be considered 
include sub involution, congenital anomalies, adherent adnexa, omentum or bowel 
benign hypertrophy, and sarcoma or carcinoma of the uterus [1]. The most common 
symptom of leiomyomata, recurrent abnormal bleeding, may be caused by any of the 
numerous conditions that affect the uterus. The definitive diagnosis in cases of uterine 
bleeding usually can be established by endometrial biopsy or fractional D&C [16].
6. Management
When uterine fibroids become symptomatic, medical or surgical treatment is 
offered to the patient, depending on her age, symptoms and future fertility desires.
A. Medical therapy includes:
• Progestins: Progestational therapy using norethindrone, medrogestone, 
and medroxyprogesterone acetate has been successful. These compounds 
produce a hypo-estrogenic effect by inhibiting gonadotropin secretion and 
suppressing ovarian function [17]. A small randomised controlled trial pre-
sented weak evidence of a reduction in fibroid size among women receiving 
lynestrenol compared with women receiving leuprolide acetate [13].
• 25 mg mifepristone produces reduction in leiomyoma size and uterine vol-
ume and produces symptomatic improvement in women with fibroids [23].
• Gonadotrophin Releasing Hormone (GnRH) agonists have proven very 
useful for limiting growth or temporarily decreasing uterine fribroid’s 
size. GnRH agonists induce hypogonadism through pituitary desensitisa-
tion, down-regulation of receptors, and inhibition of gonadotropins. They 
are however not suitable for long term use because they are associated 
with menopausal symptoms and bone loss but are likely to be beneficial 
preoperatively [24].
• Oestrogen Receptors Modulators and Antagonists: Because co-admin-
istration of oestrogen with progesterone was essential for growth and 
maintenance, inhibition of oesytogen receptors should also be an effective 
treatment for Leiomyomas [22].
Fibroids
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B. Surgical therapies include:
• Myomectomy: There may be a beneficial effect of surgical resection of 
myomas to enhance fertility or successful pregnancy outcome [25]. It 
can be achieved using the following surgical procedures: open surgery, 
laparoscopy, robotic, transvaginal, and hysteroscopic surgery. The loca-
tion and size of the myoma(s) dictates the specific surgical approach. 
Total abdominal myomectomy maintains fertility compared with 
 hysterectomy but increases recovery time and postoperative pain com-
pared with laparoscopic myomectomy [24]. However, there is high chance 
of recurrence with myomectomy, while hysterectomy is definitive. A rare 
complication of laparoscopic myomectomy is the occurrence of parasitic 
leiomyomas. They usually regress after menopause but in extremely rare 
cases they can calcify and present in a post-menopausal woman with 
atypical signs and symptoms [26].
• Hysterectomy: It is the procedure of choice whenever surgery is indicated 
for leiomyomas and when childbearing has been completed. It should 
also be considered in the event of a rapidly enlarging fibroids, in which a 
reasonable likelihood of malignancy exists. Different types of hysterec-
tomies exist: laparoscopically-assisted vaginal hysterectomy, total vaginal 
hysterectomy, total abdominal hysterectomy and total laparoscopic 
hysterectomy. Total abdominal hysterectomy is considered to be beneficial 
in reducing fibroid-related symptoms, but total vaginal hysterectomy and 
total laparoscopic hysterectomy may have lower risks of complications, 
and shorter recovery times [18]. In 2010 Demir RH and Marchand GJ pub-
lished a case report in which they resected a huge uterus weighing 3200 g 
via laparoscopic-assisted hysterectomy, laparotomy can be avoided in 
almost all instances of hysterectomy for benign disease for an experienced 
laparoscopic surgeon [27].
• Uterine artery embolization (UAE): It is the occlusion of the uterine 
artery, which reduces the blood supply to the uterus and ultimately to 
the uterine fibroids. There is evidence that uterine artery embolization 
patients are more likely to report greater improvements in symptoms, 
fewer complications and less additional interventions than myomectomy. 
Meanwhile, patients who undergo a myomectomy are more likely to have 
a conserved fertility [28, 29]. Complications of the technique include 
infections, complications of angiography and very rarely, uterine isch-
emia. However, there are no increased serious complications after UAE in 
patients with a large fibroid burden [30].
• Laparoscopic occlusion of the uterine vessel: It consists of cauterising the 
uterine artery at laparoscopy, with or without concurrent myomectomy. 
Based on the study of Helal et al. in 2010, both laparoscopic occlusions of 
the uterine vessel and embolization improve symptoms associated with 
uterine fibroids [31]. The laparoscopic procedure resulted in less postop-
erative pain and nausea and shorter hospital stays, although significantly 
more participants experienced heavy menstrual bleeding six months after 
laparoscopic occlusion, indicating a more favourable effect after uterine 
leiomyoma embolization. Thus, laparoscopic uterine artery occlusion is 
likely to attract considerable interest as an effective alternative to hysterec-
tomy treatment of symptomatic uterine leiomyomata.
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• MRI- guided focused ultrasound surgery. It was approved by the Food 
and Drug Administration (FDA) in October 2004 for the treatment of 
leiomyoma in premenopausal women who have completed childbearing. 
This outpatient procedure uses MRI for real-time thermal monitoring 
of the thermoablative technique, which concentrates multiple waves 
of ultrasound energy on a small volume of tissue to be destroyed [16]. 
Careful patient selection and use of pre-treatment imaging are important 
components for predicting the success of MR-guided focused ultrasound 
surgery of uterine leiomyomas [32]. Overall, there is reasonable toler-
ance, improvement in quality of life, and modest change in fibroid size. 
However, 11% of women experience worsened symptoms during more 
than a year of follow-up and 28% elect further treatment including 
myomectomy and hysterectomy [13].
7. Uterine Fibroids and Pregnancy.
The prevalence of leiomyomas in pregnancy varies between 10.7% to 16.7% 
[5, 33]. It’s higher in African American women followed by Caucasians, Hispanic 
and Asian women [33]. According to a study done by Hasan et al. in 2010, fibroids 
are part of the factors predictive of bleeding in the first trimester of pregnancy and 
are also potential important predictors of heavy menstrual bleeding heaviness [34]. 
This is due to the oedema, increased vascularity and hypertrophy of uterine muscles 
that lead to the increase in size of fibroids during pregnancy. However, Laughlin et 
al. in 2010 think there could be a direct protective effect of pregnancy on fibroids 
after delivery. In their study of 171 postpartum women, they found that 36% of 
fibroids resolved to an undetectable level and those that remain were reduced in 
diameter by a median of 0.5 cm [35].
Generally, the effects of fibroids on pregnancy and labour are:
• Spontaneous abortion, especially with sub-mucousal leiomyomas due to the 
distortion of the uterine cavity and impairment of the vascular supply to the 
implanted ovum [36].
• Ectopic pregnancy if it interferes with the passage of the ovum.
• Incarceration of a retroverted gravid uterus in case of posterior wall uterine 
fibroid.
• Placenta praevia due to interference with implantation of the ovum in the 
upper uterine segment.
• Malpresentations; in the study of Tchente et al. in 2008, breech presentation 
was two times more encountered in pregnant women with fibroids [15].
• Abdominal discomfort if the tumour is large.
• Torsion of the uterus which is very rare and is found in subserousal fundal 
myoma.
• Premature or threatening premature delivery probably due to the stretching of 




• Prolonged labour due to inertia from interference with normal uterine 
contractions.
• Obstructed labour in cervical myoma or pedunculated subserous myoma 
impacted in the pelvis.
• Postpartum haemorrhage due to interference with sub involution of the uterus 
and increased vascularity.
• Puerperal sepsis.
The management of uterine fibroids in pregnancy depends on the signs and 
symptoms:
In the majority of cases, no treatment is required. In case of pain, bed rest and 
narcotics are almost always successful [16]. Tocolytics may be necessary to control 
the uterine contractions in threatening premature labour. Myomectomy is generally 
contraindicated during pregnancy due to increased vascularity that may lead to 
haemorrhagic complications. However, laparoscopic myomectomy may be consid-
ered safe if done in early pregnancy but only in the hands of experienced laparo-
scopic surgeons [37]. Indications for it include red degeneration not responding to 
medical therapy, torsion of a pedunculated myoma or internal haemorrhage from 
rupture of a surface vein [36]. In case of obstructed labour, caesarean section is 
indicated but myomectomy is contraindicated. In the post-partum period, prophy-
lactic antibodies should be given. Also, the women should be carefully observed for 
post-partum haemorrhage.
8. Conclusion
Uterine fibroids are the most frequent benign uterine tumours in females of 
reproductive age. Although benign in character they are associated with adverse 
outcomes such as miscarriages, aseptic necrobiosis, foetal mal-presentation, 
obstructed labour, premature births, caesarean sections, postpartum haemorrhage 
in pregnancy, and an altered menstrual cycle, heavy menstrual bleeding, infertility, 
constipation, urinary incontinence, and malignant transformation in non-pregnant 
women. Through this chapter the authors sought to contribute to the scarce evi-
dence on its idiopathic pathophysiology and present all its available management 
options.
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